Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 0.67 |
| ▸ | CDK2 | P24941 | 12/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.67 |
| ▸ | CDK7 | P50613 | 6/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.67 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.67 |
| ▸ | CDK9 | P50750 | 4/20 | 0.67 |
| ▸ | CCNK | O75909 | 4/20 | 0.67 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.67 |
| ▸ | CDK4 | P11802 | 4/20 | 0.67 |
| ▸ | CCND1 | P24385 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | CCNH | P51946 | 4/20 | 0.67 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992709 | 1.00 | CDK1 (0.67) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL19112159 | 0.94 | CDK1 (0.70) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL30356164 | 0.94 | CDK1 (0.70) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL34470227 | 0.94 | CDK1 (0.70) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL19112165 | 0.94 | CDK1 (0.70) | CDK1CDK2CDK5CCNE1CCNB1 | |
| Hydrochloric Acid SCHEMBL30268952 | 0.93 | CDK1 (0.69) | CDK1CDK2CDK5CCNE1CCNB1 | |
| Hydrochloric Acid SCHEMBL23927314 | 0.93 | CDK1 (0.69) | CDK1CDK2CDK5CCNE1CCNB1 | |
| Hydrochloric Acid SCHEMBL23927312 | 0.93 | CDK1 (0.69) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL23752348 | 0.88 | CDK1 (0.67) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL19111944 | 0.88 | CDK1 (0.67) | CDK1CDK2CDK5CCNE1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| WO-2021214315-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-11-12 | — | — | US | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | CDK1 981/4885CDK2 1842/4885CDK5 1097/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | CDK1 2687/4885CDK2 3765/4885CDK5 1217/4885 |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | TPMT, ADORA2A, PNP | CDK1 2687/4885CDK2 3765/4885CDK5 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.